Abstract
A significant therapeutic effect in the fellow eye after intravitreal ranibizumab injections was observed in a 39-year-old diabetic male. The patient was followed-up with fluorescein angiography (FA) and Optical Coherence Tomography (OCT). On referral, best-corrected visual acuity (BCVA) was 6/60 in the right eye and Counting Fingers in the left eye. FA revealed foveal leakage in both eyes. OCT revealed diabetic and cystoid macular edema (DME-CME) in both eyes. The patient was treated with two intravitreal ranibizumab injections in the left eye. BCVA was 6/15 and 6/30 one month after the last injection. OCT revealed significant improvement (DME elimination and significant CME improvement) in both eyes, despite the fact that only the left eye was treated. It is conceivable that, in this eye, chronic vascular damage was limited and a minimal quantity of ranibizumab had a positive effect on vascular permeability, resulting in DME resolution.
This is a preview of subscription content, log in via an institution to check access.
References
Romero-Aroca P (2010) Targeting the pathophysiology of diabetic macular edema. Diabetes Care 33:2484–2485
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ (2007) Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114:2179–2182
Miki K, Miki A, Matsuoka M, Muramatsu D, Hackett SF, Campochiaro PA (2009) Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 116:1748–1754
Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K (2011) Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 27:379–383
Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803–2812
Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616–1624
Gamulescu MA, Helbig H (2010) Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J Ocul Pharmacol Ther 26:213–216
Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB (2010) Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 149:939–946
Neri P, Mariotti C, Mercanti L, Salvolini S, Giovannini A (2008) Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). Int Ophthalmol 28:425–427
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rotsos, T., Symeonidis, C., Triantafillopoulou, I. et al. Significant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eye. Int Ophthalmol 34, 1271–1274 (2014). https://doi.org/10.1007/s10792-014-9921-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-014-9921-0